12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Somatuline Autogel: Phase III data

Top-line data from the double-blind, international Phase III CLARINET trial in 204 patients with well or moderately differentiated non-functioning GEP-NETs showed that subcutaneous 120 mg Somatuline Autogel given every 4 weeks for up to 96 weeks met the primary endpoint of improving PFS vs. placebo. Data will be presented at the...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >